TFII.TO -1.7C 0.13MU -51.63CRWD 5.64PANW 6.15SNOW -4.82V -0.14MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.01
+0.10 (0.40%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
BUY

Pfizer Inc(PFE)

Feb 22, 2005
In their top 10. Great valuation.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.59

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 18, 2005
FDA has given the OK on the controversial drugs. Pfizer is a very strong company and has the best pipeline of all the large drug companies. Continues to generate billions of $'s of free cash flow. YOu won't get rich, but you'll make some money.
Photo of Andrew McCreathAndrew McCreath
Owned
Unlock Rating
$26.80

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 09, 2005
Over a 3/5 year period, it's probably OK, but it's trending down and there's no reason to get in the way of that until it changes direction. There is pricing pressure in the drug industry, product liability questions, cross border shopping , etc.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$25.05

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 07, 2005
Likes this one a lot. Trading at 11 X earnings and a 3% dividend yield and waiting to see if Cellebrex gets FDA OK. Downside is pretty limited.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$24.91

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 07, 2005
Big headline risk and he loves stock with headline risks. Trading at a 50% discount to what it's really worth.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$24.91

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 07, 2005
There is no technical sign that the ugliness has changed yet. No real strong support for the stock here. However, long term pharma sector is an interesting play.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$24.91

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 03, 2005
All the drug stocks in the US have dropped, but this had the best performance of all of them. Their Cellebrex has not been pulled and this has created some negatives. 3.2% yield and if it turns out the FDA finds no problem with the drug, it will be a major factor. Selling for 11 X earnings. Good price.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$23.91

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jan 31, 2005
FDA is becoming a lot more stricter with their criteria. Drug companies pipelines are a little bit thin now. A lot of competition. Valuations are cheaper than they've ever been. May not see any gains for a while.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$24.16

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 24, 2005
The industry as a whole has been in a difficult time. A lot of the stuff has been discounted in the stock. Trading at a very cheap multiple. Lots of cash and a high dividend yield. Good long term hold 4/5 years.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$24.26

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 21, 2005
A tough BUY, but given the valuation, if you have a 3/5 year time horizon the positives outweigh the negatives.
Photo of George LougheryGeorge Loughery
Owned
Unlock Rating
$24.48

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jan 20, 2005
Big pharmas have suffered because generics have come out of nowhere and have moved up to 50% of their business. The shine is coming off these companies and their credibility. Now trading at 12 X earnings and have a ton of cash, so could be buying back shares and improve its dividend. Good yield, but limited growth.
Photo of Ian AinsworthIan Ainsworth
No
Unlock Rating
$24.98

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 20, 2005
Could never understand the love for this stock as it was falling. It may have been oversold enough that it goes back up to $30 in the next 2 months. Long term, not very exciting.
Photo of Ron MeiselsRon Meisels
No
Unlock Rating
$24.98

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 18, 2005
(A Top Pick Oct 26/04. Down 11%.) About a 50% differential between their model price and its present price. In their top 10. Has great value.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.30

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 12, 2005
If you look at what has happened to the pharnaceuticals over the last 2 years, generally the big ethical drug companies have been very poor performers. Growth rates have dropped to low single digits. Prefers bio-tech or bio-pharmaceuticals that have growth.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$26.03

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 05, 2005
Has been hurt by the Cox-2 inhibitor problem which is in their Celbrex and Bextra. Pharmaceutical stocks in general have all been poor performers and valuations have become more reasonable, so is probably OK to start looking at them. Prefers Bristol Myers as you get a nice size dividend as they wait for a pick up.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$26.27

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
Showing 676 to 690 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG 3.18$148.69
SLB 0.68$49.59
SHEL 1.47$91.98
AAPL -24.52$308.91
AMZN 36.08$271.58
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

TFII.TO -1.7$13.38
C 0.13$132.45
MU -51.63$823.03
CRWD 5.64$190.86
PANW 6.15$331.83

Popular Articles

Latest Sell Signals

AAPL -24.52$308.91
AAPL -24.52$308.91
AAPL -24.52$308.91
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like